Literature DB >> 6982055

Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects.

I D Watson, H N Cohen, M J Stewart, S J McIntosh, A Shenkin, J A Thomson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6982055      PMCID： PMC1427639          DOI： 10.1111/j.1365-2125.1982.tb02004.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Trimethoprim. Pharmacology, antimicrobial activity and clinical use in urinary tract infections.

Authors:  A Kasanen; M Anttila; R Elfving; P Kahela; H Saarimaa; H Sundquist; R Tikkanen; P Toivanen
Journal:  Ann Clin Res       Date:  1978

2.  [Pharmacokinetic studies with the combination sulfamoxole/trimethoprim in animals and men (author's transl)].

Authors:  J Kuhne; F W Kohlmann; J K Seydel; E Wempe
Journal:  Arzneimittelforschung       Date:  1976

3.  Simplified method for determining acetylator phenotype.

Authors:  H Schröder
Journal:  Br Med J       Date:  1972-08-26

4.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

5.  Quantitative determination of the bacteriostatically active fraction of sulfonamides and the sum of their inactive metabolites in the body fluids.

Authors:  J Rieder
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

6.  Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli.

Authors:  D Greenwood; F O'Grady
Journal:  J Clin Pathol       Date:  1976-02       Impact factor: 3.411

7.  [Clinical trial of the antibacterial combination sulfamoxole/trimethoprin (CN 3123). Fifth communication: Comparison of two double-blind studies with CN 3123 undertaken for demonstration of its efficacy (author's transl)].

Authors:  J Nijssen; J Schiemann; W Wesenberg
Journal:  Arzneimittelforschung       Date:  1976

8.  Assay for trimethoprim in serum and urine by means of ion-pair chromatography.

Authors:  I D Watson; A Shenkin; S J McIntosh; H N Cohen
Journal:  Clin Chem       Date:  1980-12       Impact factor: 8.327

9.  Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim.

Authors:  B Ekström; U Forsgren; B Ortengren; T Bergan
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 10.  The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues.

Authors:  D S Reeves; P J Wilkinson
Journal:  Infection       Date:  1979       Impact factor: 3.553
View more
  6 in total

1.  Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.

Authors:  Karen Rowland Yeo; Jane R Kenny; Amin Rostami-Hodjegan
Journal:  Eur J Clin Pharmacol       Date:  2013-01-11       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

3.  Single dose pharmacokinetics of trimethoprim.

Authors:  G W Rylance; R H George; D E Healing; D G Roberts
Journal:  Arch Dis Child       Date:  1985-01       Impact factor: 3.791

4.  Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers.

Authors:  G I Adebayo; T O Ogundipe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

5.  External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole.

Authors:  Yi Shuan S Wu; Michael Cohen-Wolkowiez; Christoph P Hornik; Jacqueline G Gerhart; Julie Autmizguine; Marjan Cobbaert; Daniel Gonzalez
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.938

6.  A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.

Authors:  Denise Türk; Nina Hanke; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2020-11-10       Impact factor: 6.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.